AMICUS THERAPEUTICS, INC. — Director's Dealing 2017

Dec 6, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AMICUS THERAPEUTICS INC (FOLD)
CIK: 0001178879
Period of Report: 2017-12-04

Reporting Person: Crowley John F (Director, Chairman & CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-12-04	Common Stock	M	47213	$13.6135	Acquired	375214	Direct
2017-12-04	Common Stock	S	47213	$13.6135	Disposed	328001	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-12-04	Stock Options (right to buy)	$10.21	M	47213	Disposed	2018-02-05	Common Stock (47213)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	64895	Indirect

Footnotes

F1: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2017.

F2: This price is the weighted average purchase price for the transactions reported on this line. The prices for the transactions reported on this line range from $13.50 to $13.92. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

F3: This price is the weighted average sale price for the transactions reported on this line. The prices for the transactions reported on this line range from $13.50 to $13.92. The reporting person undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.